[Naproxen-induced pseudoporphyria].
A 12 year old boy developed scars at light-exposed areas following long-term therapy with naproxen for rheumatoid arthritis. Erythrocyte and urine porphyrin levels were not increased, and there was no evidence of increased photosensitivity. Pseudoporphyria is reported in 10-20% of those treated with naproxen for > 4 weeks. As compared to other nonsteroidal anti-inflammatory agents, the specific risk for naproxen is increased about 6fold. While the underlying abnormality has not been elucidated, formation of phototoxic metabolites in a subgroup of genetically predisposed individuals has been suggested as the most likely mechanism. Both dermatologists and rheumatologists should be aware of the risk of naproxen-induced pseudoporphyria and discontinue therapy early in order to avoid scar formation in light-exposed areas.
Maerker
J M
JM
Klinik und Poliklinik für Dermatologie und Venerologie, Bereich Pädiatrische Dermatologie, Universitätsklinikum Hamburg-Eppendorf.
Harm
A
A
Foeldvari
I
I
Höger
P H
PH
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002648:Child; D006801:Humans; D008297:Male; D009288:Naproxen / Q000008:administration & dosage / Q000009:adverse effects*; D011164:Porphyrias / Q000139:chemically induced*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009288:Naproxen